A groundbreaking study sheds new light on how gut bacteria may influence jaw pain, revealing a direct molecular link between microbial metabolites and the brain.
Gut Microbiome Metabolite Alleviates TMJ Pain in Mice
A study published in the International Journal of Oral Science on April 17, 2026, investigated the role of gut microbiome-derived butyrate in temporomandibular joint (TMJ) pain. Researchers at Texas A&M University School of Dentistry used a mouse model of inflammatory TMJ pain and administered tributyrin, a prodrug that releases butyrate. Treatment alleviated pain and restored butyrate levels in the gut, blood, and spinal trigeminal nucleus caudalis (Sp5C).
Mapping the Brain's Response at Single-Cell Resolution
Using single-cell multi-omics sequencing (snRNA-seq and snATAC-seq), the team identified 12 distinct cell types in the Sp5C, the brain region central to processing orofacial pain. They found that TMJ pain altered gene expression and chromatin accessibility without changing cell composition. Five genes—Nop14, Matk, Idh3b, Ndst2, and Tomm6—showed consistent regulatory changes that were reversed by tributyrin.
An Epigenetic Mechanism for Pain Relief
TMJ pain was associated with reduced histone acetylation in Sp5C, a key epigenetic mark that controls gene activity. This reduction was restored by tributyrin. To confirm the mechanism, researchers knocked down Nop14 in Sp5C, which led to restored histone acetylation and a significant reduction in pain behavior.
The study suggests that butyrate's analgesic effects involve epigenetic regulation via histone acetylation and transcription factor networks.
Implications for Future Therapies
These findings offer a potential new pathway for treating TMJ disorders, which affect millions worldwide. By linking gut microbiome health directly to epigenetic changes in the brainstem, the research opens the door to novel, non-invasive pain therapies targeting the gut-brain axis.